<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01563042</url>
  </required_header>
  <id_info>
    <org_study_id>114594</org_study_id>
    <nct_id>NCT01563042</nct_id>
  </id_info>
  <brief_title>A Single Dose Pharmacokinetics (PK) Study of GSK2434735 in Healthy Male Volunteers</brief_title>
  <official_title>An Exploratory First Time in Human (FTIH) Study Investigating the Pharmacokinetics (PK), Immunogenicity, Safety and Tolerability of GSK2434735 Administered as a Single Low Dose in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      An exploratory First Time in Human (FTIH) study investigating the pharmacokinetics,
      immunogenicity, safety and tolerability of GSK2434735 administered as a single low dose in
      healthy male subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Interleukin-13 (IL-13) and IL-4 are mediators in the pathogenesis of established asthmatic
      disease. GSK2434735 is a bispecific antibody to IL-13 and IL-4. The purpose of this open
      label, sequential cohort, exploratory First Time in Human (FTIH) study is to evaluate the
      pharmacokinetics (PK) profile of GSK2434735 after a single low intravenous or subcutaneous
      dose in healthy male volunteers, and to assess if the pharmacokinetics (PK) parameters can be
      scaled from monkey to man. In addition, the safety and tolerability will be monitored and the
      study will assess if antibodies are generated to GSK2434735.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 13, 2012</start_date>
  <completion_date type="Actual">May 23, 2012</completion_date>
  <primary_completion_date type="Actual">May 23, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Profile of Pharmacokinetics</measure>
    <time_frame>42 days</time_frame>
    <description>Cmax, tmax, AUC, CL, t1/2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of GSK2434735 as assessed by telemetry and change from baseline in 12-lead Electrocardiograms (ECG)</measure>
    <time_frame>42 days</time_frame>
    <description>Change from baseline for PR, RR, QRS, QT, QTc measurements at Day 42</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of GSK2434735 as assessed by change from baseline in blood pressure and heart rate</measure>
    <time_frame>42 days</time_frame>
    <description>Change from baseline for systolic and diastolic blood pressure and heart rate measurements at 42 Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of GSK2434735 as assessed by number of participants with adverse events</measure>
    <time_frame>42 days</time_frame>
    <description>Clinically relevant changes from baseline in subject's disposition at Day 42</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline for Clinical laboratory assessments (hematology, chemistry and urinalysis</measure>
    <time_frame>42 days</time_frame>
    <description>Changes from baseline values of hematologic , chemistry and urinary testing parameters at Day 42</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of human anti-drug antibodies (ADA) in blood</measure>
    <time_frame>42 days</time_frame>
    <description>Incidence of human anti-drug antibodies (ADA) at Day 42</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Cohort 1 GSK2434735</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1: Single intravenous administration of GSK2434735 and Pharmacokinetic (PK) and Immunogenicity assessments up to 42 days post dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 GSK2434735</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2: Single subcutaneous administration of GSK2434735 and Pharmacokinetic (PK) and Immunogenicity assessments up to 42 days post dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous (IV) single dose</intervention_name>
    <description>GSK2434735 administered as a single intervenous dose at the beginning of the study</description>
    <arm_group_label>Cohort 1 GSK2434735</arm_group_label>
    <other_name>GSK2434735</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Subcutaneous (SC) single dose</intervention_name>
    <description>GSK2434735 administered as a single subcutaneous dose at the beginning of the study</description>
    <arm_group_label>Cohort 2 GSK2434735</arm_group_label>
    <other_name>GSK2434735</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteers between 18 and 65 years of age

          -  Negative for pre-existing antibodies to GSK2434735.

          -  Body weight greater than and equal to 50 kg

          -  BMI 19 - 29.9 kg/m2.

          -  Lifelong non-smokers or ex-smokers of greater than 6 months

        Exclusion Criteria:

          -  Clinically significant abnormalities.

          -  Current or past history of significant cardiac, respiratory, metabolic, renal,
             hepatic, neurological or gastrointestinal conditions.

          -  Current evidence or recent history of an infective illness.

          -  Vaccination within 3 weeks of screening

          -  History of severe allergic reactions, angio-oedema, anaphylaxis or immunodeficiency
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <link>
    <url>https://www.gsk-clinicalstudyregister.com/study/114594?search=study&amp;search_terms=114594#rs</url>
    <description>Results for study 114594 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2012</study_first_submitted>
  <study_first_submitted_qc>March 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2012</study_first_posted>
  <last_update_submitted>June 19, 2017</last_update_submitted>
  <last_update_submitted_qc>June 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immunogenicity</keyword>
  <keyword>GSK2434735</keyword>
  <keyword>pharmacokinetics (PK)</keyword>
  <keyword>PK</keyword>
  <keyword>biospecific antibody</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>114594</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114594</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114594</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114594</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114594</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114594</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114594</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

